EcoDrugPlus

Thyroid Hormone Receptor Beta

Ensembl ID : ENSCJAG00000003887
Gene Symbol: THRB
5 Cross references
393 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Thyrotropin Releasing Hormone Receptor

Ensembl ID : ENSCJAG00000006433
Gene Symbol: TRHR
5 Cross references
269 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 2

Ensembl ID : ENSCJAG00000086555
Gene Symbol: TLR2
5 Cross references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 4

Ensembl ID : ENSCJAG00000065341
Gene Symbol: TLR4
5 Cross references
127 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 7

Ensembl ID : ENSCJAG00000003924
Gene Symbol: TLR7
5 Cross references
197 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 8

Ensembl ID : ENSCJAG00000003929
Gene Symbol: TLR8
5 Cross references
199 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Toll Like Receptor 9

Ensembl ID : ENSCJAG00000006069
Gene Symbol: TLR9
3 Cross references
82 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Trace Amine Associated Receptor 1

Ensembl ID : ENSCJAG00000031673
Gene Symbol: TAAR1
5 Cross references
600 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transforming Growth Factor Beta Receptor 1

Ensembl ID : ENSCJAG00000011244
Gene Symbol: TGFBR1
5 Cross references
236 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily A Member 1

Ensembl ID : ENSCJAG00000007735
Gene Symbol: TRPA1
3 Cross references
228 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily M Member 8

Ensembl ID : ENSCJAG00000014167
Gene Symbol: TRPM8
5 Cross references
158 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Transient Receptor Potential Cation Channel Subfamily V Member 1

Ensembl ID : ENSCJAG00000007063
Gene Symbol: TRPV1
3 Cross references
134 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).